Targeting vulnerability in B-cell development leads to novel drug combination for leukemia
Despite having an overall survival rate of 94%, B-cell acute lymphoblastic leukemia (B-ALL), the most common childhood cancer, can prove challenging to treat, with survival among relapsed or resistant cases falling between ...